White blood cells are the immune system’s sentinels, and their relative proportions in a blood smear are among the most diagnostically powerful numbers in medicine. A surge in neutrophils can signal a bacterial infection; a rise in lymphocytes often points to viral illness; elevated eosinophils betray allergies or parasitic invasion; and blasts—immature cells that should never appear in peripheral blood—are the alarm bell of acute leukemia. For decades, producing this picture has required a trained hematologist to scan a stained smear under a microscope and manually tally hundreds of cells, a process that is slow, expensive and vulnerable to fatigue and inter-observer disagreement. Automated hematology analyzers can count cells by the thousand, but when their results flag an abnormality, laboratories still fall back on visual microscopy review, the accepted gold standard for morphological confirmation. Deep learning promises to close that gap: a system that could triage slides automatically, standardize readings across hospitals and alert clinicians to suspicious cells within seconds would fundamentally change the economics and reliability of hematological diagnostics.

To bring order to this fast-moving literature, the team conducted a systematic literature review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses, the internationally recognized PRISMA protocol that governs how studies are searched, screened and included. Rather than simply cataloguing papers, the authors evaluated each study against an analytical framework of 18 technical dimensions, covering everything from dataset selection and preprocessing to model architecture, training strategy and reported performance. The review was organized around three research questions: which deep learning models dominate the field, how image preprocessing and segmentation shape classification performance, and what limitations and future directions define the state of the art. Studies were selected and analyzed on the basis of relevance, methodological rigor and contribution to the field. The work was funded in part by the European Union’s REFRESH—Research Excellence For Region Sustainability and High-tech Industries project and by the Ministry of Education of Czechia, and was led by corresponding author Rene Jaros of VSB–Technical University of Ostrava.

The headline statistic is unambiguous: convolutional neural networks appear in 81.6 percent of the reviewed studies, making them the undisputed backbone of white blood cell image analysis. CNNs are engineered to exploit the spatial structure of images. Instead of treating a micrograph as a flat list of pixels, they slide small filters—known as convolution kernels—across the image, each filter learning to fire in response to a specific visual pattern such as an edge, a curve, a granule or the lobed contour of a nucleus. Stacked in layers, these filters build a hierarchy of features: early layers detect simple lines and color transitions, while deeper layers assemble them into the complex shapes that distinguish a segmented neutrophil from an eosinophil or a monocyte. Crucially, such networks are rarely trained from scratch. The standard approach is transfer learning: the network is initialized with weights learned from ImageNet, a corpus of more than a million everyday photographs, and then fine-tuned on much smaller blood cell datasets, dramatically reducing the amount of scarce medical data required to reach high accuracy.

Within the CNN family, three architectures tower over the rest. ResNet, used in 32.9 percent of the studies, introduced a deceptively simple trick that transformed deep learning: residual connections, shortcut pathways that let each layer learn only the difference—a residual—between its input and the desired output. These skip connections allow gradients to flow unimpeded through dozens or even hundreds of layers during training, curing the vanishing-gradient problem that had previously made very deep networks untrainable. The Visual Geometry Group network, or VGG, chosen in 18.4 percent of studies, takes the opposite philosophical route: it relies on a plain, disciplined stack of small three-by-three convolution filters, repeated layer after layer, whose simplicity makes it easy to retrain and adapt to new cell datasets. EfficientNet, the youngest of the trio at 14.5 percent, takes a more surgical approach. Rather than scaling the network’s depth, width or input resolution independently, it scales all three together according to a compound coefficient, squeezing state-of-the-art accuracy out of a fraction of the parameters—an efficiency that matters when models must eventually run on laboratory workstations rather than data-center GPUs.

Convolutional networks are not the only players. Hybrid approaches, which combine a CNN with a second machine-learning engine, account for 11.2 percent of the literature, and their logic is straightforward: let each component do what it does best. In one common pairing, a CNN first digests a cell image and outputs a compact vector of learned features; a support vector machine then draws the final class boundaries in that high-dimensional feature space, exploiting its strength in maximizing the margin between categories. Other teams pair CNNs with long short-term memory networks—recurrent layers designed to remember information across sequences—an appealing option when cells arrive in streams from automated scanners and temporal context can inform a decision. Such hybrids persist because they pair complementary strengths: the CNN supplies rich visual representations while the second model refines the decision, sometimes at lower computational cost.

Before any network sees a cell, another family of techniques quietly shapes the outcome. Preprocessing methods, including histogram equalization, normalization and contrast enhancement, were employed in 68 percent of the reviewed studies, and for good reason. Blood smears are stained with dyes such as Giemsa or Wright’s stain, and the resulting colors vary with staining time, reagent batch, microscope illumination and the scanner or camera used to digitize the slide. Left uncorrected, this variability can cause a model trained in one hospital to fail in another. Histogram equalization redistributes the intensity values of an image so that they span the full dynamic range more evenly, stretching faint contrasts into visible ones; normalization rescales pixel values to a standard range, stabilizing the arithmetic of training; and contrast enhancement sharpens the boundary between nucleus, cytoplasm and background. Together these steps act as a common language that lets images from different laboratories, microscopes and staining protocols feed into the same model without confusing it—a quiet but decisive contributor to the accuracy figures reported across the field.

Segmentation, used in 54 percent of the studies, goes a step further by teaching the pipeline where each cell actually is. Two techniques recur most often. U-Net, an architecture originally invented for biomedical image segmentation, uses an encoder-decoder design: a contracting path that compresses the image into abstract feature maps, followed by an expanding path that reconstructs a full-resolution, pixel-by-pixel mask, with skip connections that shuttle fine spatial detail from the encoder directly to the decoder. The result is a precise outline of the nucleus and cytoplasm of every cell. The watershed algorithm works differently, treating the grayscale image as a topographic landscape in which dark nuclei form basins; flooding those basins from their minima partitions the image so that touching or overlapping cells are separated along ridge lines. Segmentation matters because morphology is diagnosis: nuclear shape, chromatin texture, granule distribution and the nucleus-to-cytoplasm ratio are exactly the features hematologists weigh, and isolating the cell from red blood cells, platelets and background debris lets a classifier focus on what counts.

The single most eye-catching number in the review is 99.83 percent: the highest classification accuracy reported anywhere in the surveyed literature, achieved with EfficientNet on the BCCD dataset, a widely used public collection of annotated blood cell micrographs. Such figures fuel the viral claim that AI now outperforms human microscopists, but the authors are careful to place them in context. Benchmark datasets are typically small, curated and carefully balanced, whereas real-world smears present overlapping cells, staining artifacts, rare cell types and scanner-to-scanner variation that no curated test set fully captures. A model that reaches near-perfect accuracy on a benchmark may lose several percentage points—or fail in unexpected ways—when confronted with data from an unfamiliar laboratory. This is why the review insists that reported accuracy must be read alongside dataset provenance, class balance and validation design. It also introduces its 18-dimension analytical framework precisely to make such comparisons honest, giving researchers a common yardstick for benchmarking existing studies rather than a patchwork of incomparable accuracy claims.

What comes next, the authors argue, is less about chasing ever-higher accuracy on familiar datasets and more about making deep learning fit for the clinic. That means models that are robust to domain shift, explainable enough for a hematologist to audit—so the system can show which visual features drove a decision—and deployable within the real workflow of a hematology laboratory. It also means larger, more diverse and more carefully annotated datasets spanning institutions, staining protocols and disease spectra, because the diversity of training data, not architectural novelty alone, will determine whether laboratory-to-laboratory generalization is achieved. The review’s structured framework is intended to guide exactly this development, steering the field toward diagnostic tools that are not merely impressive in papers but trustworthy at the bench. With white blood cell analysis sitting at the intersection of oncology, immunology and infectious disease, the stakes extend far beyond the laboratory: a dependable AI pipeline for reading blood smears could bring specialist-grade hematological assessment to hospitals and clinics that have never had a hematologist on call.

Machine learning algorithms have the capability to process vast amounts of data and identify intricate patterns that are often invisible to the human eye. Dalvi and Gawas’s comprehensive review delves into the various ML methodologies that have been implemented to detect not only anemia but also abnormalities in red blood cells (RBCs). This review is particularly significant because it synthesizes a multitude of studies and approaches, offering a clear vision of the current state of this rapidly evolving research area. With the integration of RBC indices and medical imaging data, the potential for early diagnosis becomes increasingly promising.

Through sophisticated techniques such as supervised and unsupervised learning, researchers are developing models that can predict anemia based on a wide array of input features. Supervised learning uses labeled datasets to train models, enabling them to learn distinctions between normal and abnormal conditions. Conversely, unsupervised learning explores data without pre-existing labels, allowing algorithms to uncover hidden structures. Both approaches may leverage features derived from traditional blood tests, providing a more comprehensive understanding of a patient’s health status.

In addition to the traditional lab-based indices of red blood cells, the incorporation of medical imaging offers unique opportunities for innovation. Advances in imaging techniques, including high-resolution microscopy and advanced imaging technologies, provide valuable visual data that ML models can analyze. The combination of hematological data with imaging modalities not only augments the understanding of the patient’s condition but also presents new dimensions for analysis. Analyzing images of blood samples can reveal morphological changes in red blood cells, offering insights that are pivotal for accurate diagnosis.

Moreover, the advent of deep learning, a subset of machine learning that employs neural networks with multiple layers, has revolutionized image analysis. These deep learning architectures can automatically extract salient features from images without requiring explicit programming. As a result, the models can discern fine details, such as the size and shape of blood cells, which may indicate abnormalities such as macrocytosis or microcytosis, conditions that are characteristic of various types of anemia. This sophisticated level of analysis is not only more efficient but also leads to a reduction in human error.

In their article, Dalvi and Gawas also emphasize the role of feature selection in the development of effective ML models. Feature selection involves identifying the most relevant variables that contribute to the predictive accuracy of a model. This process not only enhances model performance but also helps prevent overfitting, a common pitfall where algorithms perform well on training data but fail to generalize to new, unseen data. The ability to prioritize essential RBC indices while excluding extraneous information is crucial for building robust models capable of real-world applications.

The implications of successfully applying machine learning to anemia detection are profound. Beyond improving diagnostic accuracy, ML technologies can expedite the time it takes for patients to receive results, allowing for quicker therapeutic interventions. Doctors can make informed decisions based on data-driven insights, potentially leading to better patient outcomes. This timely response is particularly critical in emergency settings, where delays in diagnosis can have dire consequences.

Furthermore, the review highlights the essential role of interdisciplinary collaboration in advancing this research. The convergence of expertise from fields such as hematology, computer science, and biostatistics is necessary to foster innovation and develop more sophisticated models. By working together, specialists can share knowledge, refine methodologies, and help validate the performance of machine learning algorithms against established clinical benchmarks.

However, the journey toward widespread implementation of these intelligent systems is not without challenges. Issues related to data privacy, algorithm transparency, and biases in model training data must be addressed to ensure ethical practice in the deployment of machine learning tools. Furthermore, the ability to interpret the decisions made by these algorithms—often referred to as the “black box” problem—raises concerns that need to be resolved before clinical adoption can occur. Establishing regulatory frameworks and standards for validation will be paramount in addressing these ethical and practical challenges.

Moreover, ongoing research is required to fine-tune machine learning models and broaden their applicability to diverse populations. The performance of a model may be influenced by demographic factors, necessitating efforts to include a representative sample of individuals in training datasets. This will ultimately enhance the generalizability of the ML outcomes, ensuring that diagnostic tools are effective for all segments of the population.

In conclusion, Dalvi and Gawas’s review underscores the remarkable potential of machine learning in revolutionizing anemia detection and promoting better healthcare outcomes. As researchers continue to refine these technologies, the fusion of traditional medical practices with innovative computational methods will likely lead to unprecedented advancements in diagnostics and treatment. The future of anemia diagnosis can be deeply enhanced through continued exploration of this intersection, suggesting a paradigm shift that could significantly amend public health standards worldwide.

In summary, the fusion of machine learning with conventional medical practices holds tremendous promise for the diagnosis of anemia and abnormal red blood cells. As the research community advances this frontier, the time when healthcare practitioners have at their disposal effective, rapid, and precise diagnostic tools is increasingly on the horizon.

Subject of Research: Detecting Anemia and Abnormal Red Blood Cells using Machine Learning

Article Title: A Comprehensive Review of Machine Learning Approaches for Detecting Anemia and Abnormal Red Blood Cells Using RBC Indices and Medical Imaging

Article References:

Dalvi, P.T., Gawas, M.A. A comprehensive review of machine learning approaches for detecting anemia and abnormal red blood cells using RBC indices and medical imaging.
Discov Artif Intell (2025). https://doi.org/10.1007/s44163-025-00698-8

Image Credits: AI Generated

DOI:

Keywords: Machine Learning, Anemia Detection, Medical Imaging, RBC Indices, Deep Learning, Algorithm Transparency, Healthcare Innovation

Primary vitreoretinal lymphoma is notoriously difficult to diagnose because its clinical manifestations frequently overlap with those of non-malignant ocular inflammatory conditions such as uveitis. Traditionally, the diagnosis hinges upon invasive vitreous biopsies, a procedure fraught with risk, discomfort, and sometimes inconclusive results due to the paucity of malignant cells in sampled fluids. This diagnostic challenge results in delayed treatment initiation and poorer clinical outcomes. The novel machine learning model introduced by Li and colleagues circumvents these limitations by utilizing noninvasive, readily accessible blood data, paving the way for a more practical and efficient screening protocol.

The investigators harnessed comprehensive CBC data, which includes detailed metrics such as hemoglobin concentration, white blood cell differentials, platelet counts, and red blood cell indices drawn from peripheral blood samples. CBC tests are ubiquitous in clinical practice, routinely collected during standard health evaluations. By tapping into this readily available dataset, the research team aimed to detect subtle hematological signatures indicative of PVRL. Their innovative approach underscores the growing trend of repurposing commonplace clinical tests for advanced diagnostic purposes beyond their conventional scope.

Machine learning algorithms, especially ensemble models and deep neural networks, excel at discerning complex, non-linear patterns across multidimensional data. In this study, the team meticulously trained and validated several machine learning frameworks on large cohorts comprising both PVRL patients and controls with inflammatory ocular diseases. By strategically selecting and engineering features from CBC parameters, the models learned to differentiate malignant profiles from benign conditions with remarkable accuracy, sensitivity, and specificity. Notably, this highly sensitive tool serves not only as a screening instrument but also as a potential adjunct to confirmatory diagnostics, thereby optimizing clinical decision-making processes.

A pivotal aspect of this research involves the nuanced interpretation of CBC-derived biomarkers, many of which patients and clinicians routinely overlook. The investigators identified distinct hematologic perturbations correlating with PVRL pathogenesis, such as subtle shifts in lymphocyte subsets, neutrophil-to-lymphocyte ratios, and platelet distribution width. These hematological aberrations likely reflect systemic immune dysregulation and neoplastic processes associated with PVRL. The machine learning framework synthesizes this multifactorial information into a composite diagnostic risk score, enabling clinicians to stratify patients efficiently and noninvasively.

The clinical implications are profound. Early diagnosis of PVRL remains paramount, as timely initiation of chemotherapy or radiation substantially enhances survival and preserves vision. By integrating this machine learning-based screening tool into routine practice, ophthalmologists can identify high-risk patients who warrant further invasive evaluation more judiciously, reducing unnecessary biopsies and healthcare costs. Furthermore, this approach may empower non-specialists and peripheral clinics to perform initial screenings, thereby democratizing access to expert-level diagnostics and expediting referrals.

The research team undertook a robust validation process, including external cohorts from diverse geographic regions and demographic backgrounds, to ensure the model’s generalizability and resilience against confounding variables such as age, comorbidities, and treatment history. Their results demonstrated consistent performance metrics, maintaining high true positive rates while minimizing false positives. The model’s interpretability was enhanced through feature importance analyses, allowing clinicians to appreciate the biological underpinnings of the predictions and bolstering confidence in its clinical deployment.

In terms of technological innovation, this work exemplifies the convergence of hematology, oncology, ophthalmology, and artificial intelligence, highlighting the potential of multidisciplinary approaches to revolutionize disease detection. Unlike traditional imaging-based or molecular diagnostic modalities that may require expensive equipment and prolonged processing times, CBC-based machine learning screening offers a swift, cost-effective, and scalable alternative suitable for broad implementation, including resource-limited settings. This democratically accessible tool aligns well with global health priorities aiming to mitigate vision-threatening diseases worldwide.

Moreover, this noninvasive, easily repeatable screening method promises enhanced longitudinal monitoring of PVRL patients. The capacity to track hematological dynamics over the course of treatment and disease progression could facilitate personalized therapeutic adjustments and early identification of relapse. Such real-time surveillance may translate into more responsive management strategies, improved patient adherence, and ultimately, more favorable survival rates.

Beyond direct clinical applications, the findings yield insights into PVRL pathophysiology through the lens of systemic immune alterations detectable in peripheral blood. This biomarker-driven understanding can inspire future mechanistic studies exploring how lymphoma cells interact with the hematologic milieu, possibly unveiling novel therapeutic targets. Additionally, the machine learning framework is extensible and adaptable to incorporate additional biomarkers or integrate multimodal data sources, enhancing precision and robustness in lymphoma diagnostics.

Another fascinating dimension of this research is its contribution to the expanding role of artificial intelligence in personalized medicine, where algorithmic prediction models augment human expertise. As healthcare systems increasingly generate vast amounts of biomedical data, the ability to mine these data for clinically actionable insights will become indispensable. The successful application of machine learning to CBC data for PVRL screening serves as a blueprint for harnessing routine clinical information to tackle complex diagnostic challenges across various medical domains.

Importantly, the study addresses ethical and practical concerns associated with AI deployment in healthcare by emphasizing model transparency, reproducibility, and validation rigor. The authors advocate for ongoing clinical trials and real-world evaluations to elucidate the model’s ultimate impact on patient outcomes and healthcare workflows. They underscore that while promising, AI-based tools should complement rather than replace thorough clinical assessment and multidisciplinary collaboration.

The promising results herald a new era where subtle systemic signals in common laboratory tests can unlock hidden diagnoses, reducing reliance on invasive procedures and accelerating therapeutic interventions. This work stands to significantly enhance early detection of primary vitreoretinal lymphoma, a disease where every moment counts to preserve vision and life. The convergence of machine learning with routine hematology represents a paradigm shift, opening exciting avenues for future diagnostic innovation and patient-centered care in ocular oncology and beyond.

In conclusion, the pioneering study by Li and colleagues marks a transformative juncture in ophthalmic cancer diagnostics. By repurposing complete blood counts combined with sophisticated machine learning algorithms, they have crafted a potent, noninvasive screening tool tailored for primary vitreoretinal lymphoma—a disease notoriously difficult to detect early. This breakthrough not only facilitates timely identification but also exemplifies the profound potential of integrating artificial intelligence and routine clinical data to revolutionize medical diagnostics on a global scale. As future work expands on these foundations, patients worldwide may benefit from faster, safer, and more accessible cancer detection.

Subject of Research: Primary vitreoretinal lymphoma screening using machine learning applied to complete blood count data

Article Title: A noninvasive machine learning model using a complete blood count for screening of primary vitreoretinal lymphoma

Article References:
Li, S., Cao, J., Li, D. et al. A noninvasive machine learning model using a complete blood count for screening of primary vitreoretinal lymphoma. Nat Commun 16, 10667 (2025). https://doi.org/10.1038/s41467-025-65693-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65693-0